Aprocitentan Shows Promise for Managing Resistant Hypertension in CKD Patients

Managing blood pressure is a constant battle for people living with chronic kidney disease (CKD). For many, standard medications aren’t enough, leading to a condition known as resistant hypertension. This creates a dangerous cycle: hypertension is both a cause and a consequence of kidney disease, making these patients particularly difficult to treat.

Recent data from a post hoc analysis of the PRECISION trial suggests a new path forward. Aprocitentan (marketed as Tryvio), an endothelin receptor antagonist (ERA), has demonstrated the ability to safely lower blood pressure and reduce proteinuria in patients with CKD and resistant hypertension.

The Challenge of Resistant Hypertension in CKD

Resistant hypertension occurs when blood pressure remains above target despite the utilize of three or more antihypertensive drugs. In patients with CKD, this condition is common and often complicates the progression of kidney failure. According to study co-author Dr. John Flack, trying to control blood pressure in this group is a critical step in reducing their overall cardiovascular risk.

How Aprocitentan Works

Aprocitentan targets the endothelin pathway, a system in the body that can cause blood vessels to constrict. By blocking these receptors, the drug helps relax blood vessels and lower systemic blood pressure. In the PRECISION trial, this medication was added to a standardized fixed-dose combination of amlodipine, valsartan, and hydrochlorothiazide.

Key Findings from the PRECISION Trial

The analysis focused on a subgroup of 147 patients classified as high-risk or very high-risk based on KDIGO criteria, drawn from a larger group of 730 patients with resistant hypertension. The results were encouraging:

• Blood Pressure Reduction: The drug significantly reduced both office and ambulatory blood pressure.
• Nighttime Control: Researchers observed greater blood pressure-lowering effects at night compared to during the day.
• Proteinuria Improvement: There was a notable reduction in the urine albumin-to-creatinine ratio (UACR), which is a key marker of kidney damage.

Because of these results, investigators suggest that aprocitentan may represent the preferred choice for patients with uncontrolled hypertension and advanced CKD to improve BP control and reduce proteinuria.

Safety and Tolerability

One of the primary concerns when introducing new medications to CKD patients is the impact on kidney function and electrolyte balance. The post hoc analysis found that aprocitentan was well-tolerated, with a safety profile similar to the general trial population.

Critical Safety Observations:

• Kidney Function: There were no major changes in the estimated glomerular filtration rate (eGFR).
• Electrolytes: No significant changes were seen in sodium or potassium levels.
• Edema: A risk of edema (swelling) was observed, though this was largely confined to the first month of treatment. Specialists note that this side effect is manageable.

Key Takeaways for Patients and Providers

Looking Ahead

The ability to control blood pressure in high-risk CKD patients is vital for preventing further cardiovascular and renal decline. As evidence grows from the PRECISION trial analysis, aprocitentan stands out as a potent tool for clinicians managing some of the most challenging cases of resistant hypertension.